Espinosa-Bustos Christian, Lagos Carlos F, Romero-Parra Javier, Zárate Ana M, Mella-Raipán Jaime, Pessoa-Mahana Hernán, Recabarren-Gajardo Gonzalo, Iturriaga-Vásquez Patricio, Tapia Ricardo A, Pessoa-Mahana C David
Department of Pharmacy, Faculty of Chemistry, Pontificia Universidad Catolica de Chile, Santiago, Chile.
Arch Pharm (Weinheim). 2015 Feb;348(2):81-8. doi: 10.1002/ardp.201400201. Epub 2015 Jan 13.
A series of N-acyl-2,5-dimethoxyphenyl-1H-benzimidazoles were designed based on a CoMFA model for cannabinoid receptor type 1 (CB1) ligands. Compounds were synthesized and radioligand binding affinity assays were performed. Eight novel benzimidazoles exhibited affinity for the CB1 receptor in the nanomolar range, and the most promising derivative compound 5 displayed a K(i) value of 1.2 nM when compared to CP55,940. These results confirm our previously reported QSAR model on benzimidazole derivatives, providing new information for the development of small molecules with high CB1 affinity.
基于大麻素1型(CB1)受体配体的比较分子场分析(CoMFA)模型,设计了一系列N-酰基-2,5-二甲氧基苯基-1H-苯并咪唑。合成了化合物并进行了放射性配体结合亲和力测定。八种新型苯并咪唑在纳摩尔范围内对CB1受体表现出亲和力,与CP55,940相比,最有前景的衍生物化合物5的K(i)值为1.2 nM。这些结果证实了我们之前报道的关于苯并咪唑衍生物的定量构效关系(QSAR)模型,为开发具有高CB1亲和力的小分子提供了新信息。